The Icatibant Outcome Survey: 10years of experience with icatibant for patients with hereditary angioedema

• Published in: Clinical and experimental allergy Vol. 52; no. 9; pp. 1048 - 1058
• Main Authors: Maurer, Marcus, Aberer, Werner, Caballero, Teresa, Bouillet, Laurence, Grumach, Anete S, Botha, Jaco, Andresen, Irmgard, Longhurst, Hilary J
• Format: Journal Article
• Language: English
• Published: Oxford Wiley Subscription Services, Inc 01.09.2022
• Subjects: Angioedema; Bradykinin; Bradykinin B2 receptors; Clinical trials; Complement component C1; Edema; Patients; Surveys
• ISSN: 0954-7894; 1365-2222
• DOI: 10.1111/cea.14206

In patients with hereditary angioedema (HAE), bradykinin causes swelling episodes by activating bradykinin B2 receptors. Icatibant, a selective bradykinin B2 receptor antagonist, is approved for on‐demand treatment of HAE attacks. The Icatibant Outcome Survey (IOS; NCT01034969) is an ongoing observational registry initiated in 2009 to monitor the effectiveness/safety of icatibant in routine clinical practice. As of March 2019, 549 patients with HAE type 1 or 2 from the IOS registry had been treated of 5995 total attacks. This article reviews data published from IOS over time which have demonstrated that the effectiveness of icatibant in a real‐world setting is comparable to efficacy in clinical trials; one dose is effective for the majority of attacks; early treatment (facilitated by self‐administration) leads to faster resolution and shorter attack duration; effectiveness/safety of icatibant has been shown across a broad range of patient subgroups, including children/adolescents and patients with HAE with normal C1 inhibitor levels; and tolerability has been demonstrated in patients aged ≥65 years. Additionally, this review highlights how IOS data have provided valuable insights into patients' diagnostic journeys and treatment behaviours across individual countries. Such findings have helped to inform clinical strategies and guidelines to optimise HAE management and limit disease burden. This research was sponsored by Takeda Development Center Americas, Inc. Takeda Development Center Americas, Inc., provided funding to Excel Medical Affairs for support in writing and editing this manuscript.